Analyst team at Baird upgraded Albemarle to an outperform rating from neutral and lifted its 12-month price target to 210 from 113, citing robust global lithium consumption that has outstripped supply for three consecutive quarters. The firm pointed out that lithium carbonate and hydroxide contract prices in Asia have climbed over 40% since November, driven by new battery plant ramp‐ups in South Korea and China. Baird noted that Albemarle’s asset utilization at its Chemetall and La Negra operations averaged 92% in the most recent quarter, up from 85% a year earlier, and forecasted a 25% jump in lithium segment EBITDA next year.

Albemarle shares have recorded four straight advances, including its largest one‐day gain since October, pushing the equity to levels not seen in two years. Over the past nine months the stock has surged approximately 168%, outperforming both the S&P 500 and peer chemical producers. Technical indicators show the share price has held above its 20‐day moving average continuously since early November, signaling sustained buying interest from institutions and algorithm-driven funds.

Put/call volume ratios across the International Securities Exchange, Cboe Options Exchange and Nasdaq indicate a 50-day ratio of 1.09, placing it in the highest 7th percentile of readings over the past year. Such elevated pessimism in the options pits may be poised to reverse, creating tailwinds for the equity. At the same time, Albemarle’s Schaeffer’s Volatility Index stands at 55%, above 88% of its historical observations, implying that option premiums remain relatively modest and could be attractive to bullish speculators betting on continued price appreciation.